Current Trials
ECHO Open to Acrrual Clinical Trials
Updated: 6/16/21
| Bladder / Urothelial Muscle Invasive Alliance A031701 A Phase II study of Dose-Dense Gemcitabine plus Cisplatin (DDGC) in patients with Muscle-Invasive Bladder Cancer with Bladder preservation for those patients whose tumors harbor deleterious DNA Damage Response (DDR) Gene alterations SGN22E-002 / EV-103 A Study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer SGN22E-003 / EV-302 An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. Colorectal Metastatic NRG-GI004 / SWOG-S1610 *Temperarily Closed* Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer MRT 849-010 / Krystal-10 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy Lung ARRAY-818-202 A Phase II, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFv600E-Mutant Non-Small Cell Lung Cancer ARRAY-818-202 Emerge 402: Phase IV Observational Study to Collect Safety and Outcome ata in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca A151216 Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) D910LC00001 MERMAID-1 A phase III, Randomized, Multicenter, Double-blind, Placebo-controlled study to determine the efficacy of Adjuvant Durvalumab in combination with Platinum-based Chemotherapy in completely Resected Stage II-III NSCLC (mermaid-1) D910MC00001 MERMAID-2 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy E4512 A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein First Line Metastatic GSK 213400 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comparing Niraparib plus A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as maintenance Therapy in participants whose disease has remained stable or responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer (Zeal-1L) Mirati 849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation Second Line Metastatic GSK 213410 A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (Costar Lung) Mirati MRT516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Lymphoma D8227C00001 / ACE-LY-312 / Escalade A phase 3, Randomized, Double-Blind, Placebo-controlled study of Acalabrutinib in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects 65 years or younger with previously untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Melanoma ECOG EA6134 Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma Prostate Cancer 64091742PCR0002 / TIME / Prevalence Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer LAE201INT2101 A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment NRG-GU002 A Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel Solid Tumors ML42439 /MYTACTIC An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors with Genomic Alterations or Protein Expression Patterns predictive of response SGNLVA-005 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors Screening Lung Screening I-ELCAP International Early Lung Cancer Action Program: Enrollment and Screening Protocol Supportive Care Ready 1 / CUSA-081-HEM-01 /YYA36723 Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs) Seer – 020102 (SeerPro) A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers THR-CS-001 / THRIVE / DETECT-ASCEND 2 Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for DysfuncExact Sciences Thrive LLC / Detecting Cancers Earlier Through Elective Plasma-Based CancerSEEK Testing – Ascertaining Serial Cancer Patients to Enable New Diagnostic II (DETECT-ASCEND 2) |
For more information on clinical trials, please contact: Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.